iSpecimen to Participate in Maxim’s 2022 Virtual Growth Conference on March 28-30, 2022

3 years ago

LEXINGTON, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), a global, proprietary online…

Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

3 years ago

Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral…

Quipt Home Medical to Participate at the Sidoti Virtual Investor Conference On March 23rd – 24th

3 years ago

Sidoti Webcasted Presentation to be Held Wednesday March 23rdCINCINNATI, March 15, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the…

Acerus Reports Fourth Quarter and Full Year 2021 Financial Results

3 years ago

TORONTO, March 15, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported…

Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series

3 years ago

– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared…

Burning Rock to Release MRD Clinical Data on NSCLC and CRC at the Upcoming American Association for Cancer Research Annual Meeting

3 years ago

GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today…

Kamada Issues 2022 CEO Letter to Shareholders

3 years ago

REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company,…

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results

3 years ago

Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 20212022 Guidance Reaffirmed BOSTON and LAUSANNE, Switzerland, March…

Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

3 years ago

Data readouts from multiple clinical trials expected during the next 6 to 12 months Strong cash position of $190.3 million…

Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022

3 years ago

DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company…